Jazz Pharmaceuticals (JAZZ) Liabilities and Shareholders Equity (2010 - 2026)

Jazz Pharmaceuticals' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $11.9 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 2.82% year-over-year to $11.9 billion in Q1 2026; TTM through Mar 2026 was $45.8 billion, a 2.85% decrease from a year earlier, with the FY2025 full-year figure at $11.7 billion, down 2.94% from the prior year.
• Liabilities and Shareholders Equity improved to $11.9 billion in Q1 2026 per JAZZ's latest filing, from $11.7 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $12.3 billion in Q3 2024 and bottomed at $10.4 billion in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $11.4 billion (2025), against an average of $11.4 billion.
• Biggest YoY gain for Liabilities and Shareholders Equity was 74.19% in 2022; the steepest drop was 16.78% in 2022.
• Year by year, Liabilities and Shareholders Equity stood at $10.8 billion in 2022, then increased by 5.15% to $11.4 billion in 2023, then advanced by 5.43% to $12.0 billion in 2024, then fell by 2.94% to $11.7 billion in 2025, then grew by 1.72% to $11.9 billion in 2026.
• Per Business Quant, the three latest JAZZ Liabilities and Shareholders Equity figures stand at $11.9 billion (Q1 2026), $11.7 billion (Q4 2025), and $11.4 billion (Q3 2025).